Screener
Maze Therapeutics MAZE Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Maze Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Maze Therapeutics’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:48 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344903
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Purchases of marketable securities | (186,031) | — |
| Maturities of marketable securities | 64,000 | — |
| Purchases of property and equipment | (200) | (692) |
| Net cash used in investing activities | (122,231) | (692) |
| Financing activities | ||
| Proceeds from underwritten registered offering, net | 145,659 | — |
| Payment of underwritten registered offering costs | (1,090) | — |
| Proceeds from debt issuance, net | 39,401 | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Maze Therapeutics's investing cash flow?
- Maze Therapeutics (MAZE) reported investing cash flow of -$128.51M in Q2 2026.
- How has Maze Therapeutics's investing cash flow changed year-over-year?
- Maze Therapeutics's investing cash flow decreased by 32598.7% year-over-year, from -$393K to -$128.51M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Maze Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude